Clinical trials: First Line Treatment
Carcinoma, Non-Small-Cell Lung, Immunotherapy
Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)
This study was a French multicentric cross-sectional study retrospectively of 108 consecutive advanced NSCLC patients with a PD-L1 TPS ≥50% and without EGFR/ALK aberrations treated by pembrolizumab in first line.
- Trial name
- PEMBREIZH (NCT05321212)
- Where
- 2 sites in France
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Helicobacter
Sequential Therapy Versus Quadruple Therapy in H. Pylori Eradication
The investigators aimed to 1. compare the eradication rates and long term re-infection rates of sequential therapy for 14 days versus bismuth quadruple therapy for 10 days in the first line and second line treatment 2.
- Trial name
- NCT03156855
- Testing
- 14-day sequential therapy, Bismuth quadruple therapy
- Where
- 7 sites in Taiwan
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression
JAK2 Mutation May Predict Response and Guide First Line Treatment in Rheumatoid Arthritis
This study included 76 newly diagnosed RA patients and 50 matched controls. Basal JAK2 mutation was assessed by PCR in blood samples, TNF-α and IL 6 were measured by ELISA in serum of patients and controls.
- Trial name
- NCT04667988
- Testing
- JAK expression
- Where
- Egypt
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Mansoura University
Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
This is a Phase 3, open-label single-arm trial designed to evaluate the safety and efficacy of NDV-01 (sustained-release gemcitabine-docetaxel) in adult participants with NMIBC with CIS who have failed BCG therapy and who have…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Trial name
- RESCUE (NCT07342517)
- Testing
- NDV-01 (sustained-release gemcitabine-docetaxel)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Relmada Therapeutics, Inc.
Locally Recurrent and Metastatic Breast Cancer
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
This is a phase 2, randomized, placebo controlled, multi-center study to estimate the treatment effect and evaluate the safety and tolerability of AMG 386 in combination with paclitaxel and paclitaxel/bevacizumab in the treatment…
- Trial name
- NCT00511459
- Testing
- AMG 386, Bevacizumab, Paclitaxel
- Where
- 77 sites in United States, Australia and 11 more
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Amgen
Pain Management
MBCT for Cancer Patients in Follow-Up
The objectives of the present study are: 1) to executing the practical implementation in an oncology department of MBCT for patients who have completed their primary treatment and experience significant cancer- and…
- Trial name
- NCT03591237
- Testing
- Mindfulness-Based Cognitive Therapy
- Where
- 2 sites in Denmark
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Knowledge, Attitudes, Practice, Low Back Pain
Effect of an E-learning Intervention on Knowledge, Attitudes and Beliefs of Healthcare Professionals Managing Low Back Pain.
The purpose of the current research project is to examine if the healthcare professionals (HCPs) knowledge, attitudes, beliefs and behavior about the management of low back pain (LBP) patients changes following an e-learning…
- Conditions
- Knowledge, Attitudes, Practice, Low Back Pain, Physical Therapy, Physicians
- Trial name
- NCT05284669
- Testing
- Experimental e-learning, Traditional e-learning
- Where
- Belgium
- Volunteers
- 2,720 people, healthy volunteers welcome
- Sponsor
- Antoine Fourré
Helicobacter Infections
Levofloxacin Versus Clarithromycin Triple Therapy in First-Line Treatment for Helicobacter Pylori Eradication
Clarithromycin-based triple therapy containing a proton-pump inhibitor (PPI) twice daily, amoxicillin 1g twice daily, and clarithromycin 500 mg twice daily for 7 days is one of the standard firs-line therapy for Helicobacter…
- Trial name
- NCT00816140
- Testing
- Cravit based triple therapy, Klaricid based triple therapy
- Where
- Taiwan
- Volunteers
- 432 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Pancreatic Adenocarcinoma Metastatic
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer
This is a multi-center, open-label， randomized controlled Phase II clinical study to observe and evaluate the efficacy and safety of Penpulimab combined with Anlotinib and Nab-paclitaxel plus Gemcitabine (PAAG ) versus AG…
- Trial name
- RCT-PAAG (NCT06051851)
- Testing
- Penpulimab, Anlotinib, Nab paclitaxel
- Where
- China
- Volunteers
- 177 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Locally Advanced Urothelial Carcinoma, Oligo-metastaic Urothelial Carcinoma
Consolidative Local Therapy (CLT) in Oligo-metastatic Urothelial Carcinoma
This study investigates the therapeutic benefit of consolidative local therapy with extirpative surgery for participants with locally advanced or oligo-metastatic urothelial carcinoma that have disease control with enfortumab…
- Trial name
- CONSOLIdATE-1 (NCT07048457)
- Testing
- Radical cystectomy
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Yale University
Helicobacter Pylori Infection
Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection
Whether non-bismuth quadruple therapy (concomitant therapy) is more effective than bismuth quadruple therapy or triple therapy for 14 days remains unknown.
- Trial name
- NCT01906879
- Testing
- triple, quadruple, non-bismuth quadruple therapy
- Where
- 10 sites in Taiwan
- Volunteers
- 1,620 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Lung Cancer, Esophageal Cancer
A Multi Tumor, Open Phase I Clinical Study on the Progression of First-line Anti-tumor Therapy Using Cardonizumab Combined With Pulsed Low-dose Rate External Irradiation (PLDR)
At present, the treatment methods for recurrent cancers are very limited. The immune checkpoint inhibitors (ICBs) is a promising new directions for recurrent lung cancer/ esophageal cancer / cervical cancer, but the clinical…
- Conditions
- Lung Cancer, Esophageal Cancer, Cervical Cancer
- Trial name
- NCT06232083
- Testing
- PLDR+Cardunizumab
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Anhui Provincial Hospital
Helicobacter Pylori Eradication, Adverse Reaction
Tegoprazan-Based Therapies for H. Pylori Eradication: A Randomized Controlled Trial
Current first-line Helicobacter pylori eradication protocols involve multidrug regimens comprising a proton pump inhibitor (PPI) or bismuth agent combined with dual antibiotics (e.g., clarithromycin, amoxicillin, quinolones…
- Trial name
- NCT06977841
- Testing
- Tegoprazan, Amoxicillin, Tetracycline
- Where
- China
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
HIV-1-infection
A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy
This is an open label, randomised, phase 3, two-arm study conducted over 96 weeks. The study includes a screening period day - 60 to -1, enrolment visit day 0, and a 96-week treatment follow-up period.
- Trial name
- Opti-DOR (NCT05924438)
- Testing
- Delstrigo, KOCITAF
- Where
- South Africa
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Professor Francois Venter
Ovarian Cancer
Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer
Fluzoparib has been approved for the first-line maintenance treatment of advanced ovarian cancer in the full population . Previous studies have demonstrated that anti-angiogenic agents enhance tumor cell sensitivity to PARP…
- Trial name
- NCT06954584
- Testing
- Bevacizumab, Fluzoparib Monotherapy, Dietary Intervention
- Where
- 2 sites in China
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Tuberculosis
PK Study of Anti-TB Drugs
This is a prospective descriptive and pharmacokinetic study will be conducted among newly diagnosed patients registered in the two SMRU TB clinics located on the Thai-Myanmar border.
- Trial name
- NCT02457208
- Testing
- Isoniazid (H), Rifampicin (R), Pyrazinamide (Z)
- Where
- Thailand
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Biliary Tract Cancer
Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers
This study is to evaluate the response rate and toxicity profile of infusional 5 fluorouracil, leucovorin, oxaliplatin and irinotecan (FOLFIRINOX) in first-line treatment of advanced biliary tract cancers and also to assess…
- Trial name
- FBI-TRAC (NCT03291899)
- Testing
- FOLFIRINOX
- Where
- Saudi Arabia
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- King Faisal Specialist Hospital & Research Center
Non-small Cell Lung Cancer
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
EGFR mutation positive advanced NSCLC patients with uncleared ctDNA have poor prognosis, whether they can benefit from combination therapy has not been reported.
- Trial name
- FOCUS-C (NCT05334277)
- Testing
- Furmonertinib, Furmonertinib/Pemetrexed/Carboplatin, Furmonertinib/Pemetrexed/Carboplatin/Bevacizumab
- Where
- 26 sites in China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Glabellar Frown Lines
AI-09 In Subjects With Glabellar Lines, GL-101
AI-09 In Subjects with Glabellar Lines
- Trial name
- NCT05565950
- Testing
- AI-09, Vehicle
- Where
- 4 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Eirion Therapeutics Inc.
Periorbital Wrinkles
Safety and Efficacy of XP200 Radiofrequency Treatment of Wrinkles
To evaluate the wrinkle-reducing effects of 3.25-MHz radiofrequency (RF) energy delivered in 4 weekly applications to human periorbital skin area by grating pre- and 90-days post treatment photographs on the Fitzpatrick Wrinkle…
- Trial name
- NCT01795417
- Testing
- RF XP200, XP200 RF device
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- BTL Industries Ltd.